ProPublica

Journalism in the Public Interest

Cancel

The Trade

Now What? Failed Allergan Deal Strains Valeant

.

Michael Pearson, chief executive of Valeant, pauses during an interview in April. In January, Pearson articulated a plan to become a Top Five pharmaceutical company by the end of 2016. (Scott Eells/Bloomberg via Getty Images)

Read More »

The Real Roots of Hedge Fund Manager Rage

The Big Bank Backlash Begins

Nice Little Agency You Got There

The Fed Hates To Burst Your Bubble

The Sorry State of Bank Apologies

Mary Jo White was Supposed to Turn Around the S.E.C. She Hasn’t.

The new chairwoman of the S.E.C., has made some unnecessary foes while her agency has bungled several significant regulatory rules.

Does Valeant’s Cost-Cutting Go Too Far?

Valeant ​Pharmaceuticals dragged its feet on a safety study mandated by the FDA and ran into manufacturing problems, consequences of its desire to keep costs low, according to current and former executives.

BlackRock Doesn’t Need A Scarlet Letter

The S.E.C. has a point on asset managers but it is undermining financial regulation with its public and needless antagonism of the Financial Stability Oversight Council
Jesse Eisinger

About The Trade

In this column, co-published with New York Times' DealBook, I monitor the financial markets to hold companies, executives and government officials accountable for their actions. Tips? Praise? Contact me at .(JavaScript must be enabled to view this email address)